![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
October 24, 2024
Tweets
;
Do you have HER2-positive breast cancer? If so, you may be eligible to participate in the phase 2 #ClinicalTrial EA1211/DIRECT, testing if FDG-PET/CT imaging can better predict a patient's response to treatment than the usual approach. Learn more: https://bit.ly/EA1211
Behind the @EAonc E1910 trial: blinatumomab in patients with B-cell acute lymphoblastic leukemia. The trial results show a significant survival advantage with blinatumomab immunotherapy and contributed to its recent FDA approval for these patients. #leusm @TargetedOnc
Kicking off #LungCancerAwarenessMonth with a message of hope from #lungcancer survivor + @ALKPositiveinc 🌟, Kirk!
⬇️ photo below from famous #Nashville “What Lifts You” mural. Pts like Kirk lift me every day with their passion, fortitude, strength, + hope 🫁 🩵🙏 @IASLC
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
45
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
